Importantly, pharmacological inhibition of EZH2 restored cell surface MHC-I in K-562 and cell lines representative of neuroblastoma, SCLC, and MCC, a neuroendocrine cancer recently shown to escape from immunotherapy through transcriptional downregulation of MHC-I genes (Figure 2C) (Paulson et al., 2018). This evidence concerns the gene EZH2 and neuroendocrine carcinoma.